- SID Score
- 7.3/10
- Fair value
- $108.28
- Generated
- Sep 3, 2026
- Model
- claude-haiku-4-5-20251001
AstraZeneca trades at $161.63 with a market capitalization of $279.9 billion, significantly above its fair value estimate of $108.28, suggesting the stock is currently overvalued by approximately 33.4%. The company demonstrates strong growth characteristics (Grade A) supported by recent earnings beats, though its elevated P/E ratio of 33.06x and minimal dividend yield of 0.02% reflect premium valuation expectations. With a SID Score of 7.3/10 and "Buy" consensus from analysts, the market is pricing in substantial future performance, yet current valuations present considerable downside risk for new investors.
AstraZeneca exhibits mixed fundamental health with strong growth prospects offset by concerning valuation metrics and moderate profitability concerns (Grade C). Recent earnings have consistently exceeded expectations, with Q2 2026 EPS reaching $2.63 against estimates of $1.52 and Q1 2026 delivering $2.58 versus $1.53 estimated, demonstrating operational execution capability. However, the company's Value grade of F indicates significant overvaluation relative to earnings and book value, while the P/E ratio of 33.06x far exceeds typical healthcare sector averages of 15-20x, suggesting market expectations may be unrealistic or dependent on major pipeline successes.
The stock exhibits neutral momentum with RSI(14) at 59.3, indicating neither overbought nor oversold conditions, positioning it near technical equilibrium. Price action shows the stock trading near its 50-day moving average of $169.93 but has stabilized above the 200-day moving average of $159.61, suggesting intermediate support levels are holding. The current price represents only a 5% decline from the 50-day MA, indicating the stock remains at elevated levels despite fair value estimates suggesting 33% downside potential.
Analyst & Insider Sentiment
Analyst consensus remains "Buy" with an average price target of $102.67, which paradoxically conflicts with the current stock price of $161.63, implying consensus expectations for a 36.5% decline from current levels. Insider activity presents a constructive signal, with Sharma Mani executing systematic monthly purchases of approximately 19,263 shares since June 2026, demonstrating management confidence in long-term value despite recent volatility. This insider accumulation pattern contrasts sharply with analyst price targets, creating conflicting signals regarding appropriate valuation.
The primary risk facing AstraZeneca is valuation compression, as the stock trades at a substantial premium to both analyst targets and estimated fair value, creating vulnerability to earnings disappointments or macroeconomic headwinds. Profitability concerns (Grade C) and a minimal dividend yield (0.02%) suggest the investment case relies heavily on growth realization and pipeline success, leaving limited margin of safety for investors. Additional risks include pharmaceutical industry-specific challenges such as regulatory pressures, patent expirations, and clinical trial outcomes for pipeline candidates that could materially impact the justified premium valuation.
AstraZeneca represents a growth-oriented investment suitable primarily for long-term portfolio holders who believe the company's pipeline and operational execution justify current premium valuations, though the risk-reward profile is unfavorable for value-conscious investors seeking margin of safety. The combination of strong recent earnings beats, insider accumulation, and "Buy" consensus supports the investment quality, but the 33% divergence between current price and fair value estimate presents significant downside risk. Conservative investors should await either a material price correction toward the $102-$108 range or improved profitability metrics before initiating positions, while growth investors may justify entry given the Grade A growth profile and demonstrated execution capability.
